Heart FailureMOVIN-HFNCT07750262
Mobile Health Intervention to Increase Activity in Heart Failure Study
A study testing Mobile application intervention in people with Heart Failure, run by University of Michigan at 1 site in United States.
Trial summary
Physical activity is known to help patients with heart failure feel better and live longer though few patients with heart failure are sufficiently active. This study is evaluating whether a mobile health intervention can help patients with heart failure increase physical activity levels and remain active over time. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Heart Failure
- What is being tested?
- Mobile application intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 12 Aug 2026to Nov 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Michigan Medicine patient with a diagnosis of heart failure (HF)
- Age 18 years and older at screening and able to provide consent
- New York Heart Association class 2 or 3 HF symptoms
- Safe for home physical activity as determined by treating clinician
- Own a smartphone with a compatible Apple or Android operating system
- Fluent in spoken and written English
Who cannot join
- Hospitalized for HF within the prior 6 weeks
- Orthopedic or neurological condition significantly limiting physical activity
- Greater than mild cognitive impairment
- Enrolled in hospice care
- Severe valvular stenosis
- Exercise-induced ventricular tachycardia
Show all 10Show fewer
- Obstructive left main or proximal left anterior descending coronary artery disease
- Pulmonary hypertension treated with inhaled or intravenous therapy
- Currently pregnant or planning to become pregnant
- Determined to be unsafe for participation as assessed by the investigative team.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Michigan
Ann Arbor, Michigan, 48109
Chelsie Gesierich, MPH, 734-998-0514, MOVIN-HF-Study@med.umich.edu
Jessica Golbus, MD, MS
About this study
Official title: MObile Health Intervention to INcrease Activity in Heart Failure Study: A Micro-Randomized Trial
Physical activity is known to help patients with heart failure feel better and live longer though few patients with heart failure are sufficiently active. This study is evaluating whether a mobile health intervention can help patients with heart failure increase physical activity levels and remain active over time. The mobile health intervention consists of three parts: Notifications encouraging physical activity, a digital health coach trained in motivational interviewing, and a mobile application which encourages goal setting and activity monitoring.
Read the detailed description
Hypotheses:
- Push notifications as part of a mobile health intervention will increase immediate (4 hour) physical activity levels among participants with heart failure.
- A multicomponent mobile health intervention will increase physical activity levels at 3 months among participants with heart failure.
- An artificial intelligence (AI) based health coach promoting physical activity will be safe among participants with heart failure.
- Conditions
- Heart Failure
- Being tested
- Mobile application intervention
- Keywords
- Physical activity, Digital health, Mobile Health, Artificial Intelligence
- Medical subject headings
- Heart Failure, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mobile application interventionBehavioural
Following a baseline period, participants will receive a 12 week mobile health intervention consisting of 3 main components: (1) a mobile application which supports goal-setting and self-monitoring; (2) an artificial intelligence (AI)-based health coach within the mobile application trained in principles of motivational interviewing and tailored to the needs of patients with heart failure (3) micro-randomized messages designed to enhance perceived competence around physical activity and promoting low level physical activity.
| Study group | Role | What they receive |
|---|---|---|
| Mobile application intervention | Experimental | All participants will have a 1-week baseline period to establish participants pre-intervention step counts. Receives: Behavioral: Mobile application intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Step count 4 hours after a decision point for micro-randomized messages
Measured: 4 hours after a decision point
Secondary outcomes (5)
Change in mean daily step count from baseline to 3 months
Participants will wear a Fitbit activity tracker for the duration of the study
Measured: Baseline, 3 months
Percentage of transcripts with a recommendation that is deemed unsafe by the study team
AI-based health coaching conversations determined to be unsafe based on study team review.
Measured: 3-month intervention
Changes in autonomous motivation from baseline to 3 months on the Behavioral Regulation in Exercise Questionnaire version 3 (BREQ-3)
The BREQ-3 is a widely used measure of the continuum of behavioral regulation in exercise psychology research. The BREQ-3 is 24 questions and the score ranges from 0-4 with higher scores indicating a greater level of endorsement of autonomous motivation. It will be measured at 2 time points. Autonomous motivation will be calculated by combining the identified, integrated, and intrinsic regulation subscales of the BREQ-3.
Measured: Baseline, 3 months
Change in controlled motivation from baseline to 3 months on the Behavioral Regulation in Exercise Questionnaire version 3 (BREQ-3).
The BREQ-3 is a widely used measure of the continuum of behavioral regulation in exercise psychology research. The BREQ-3 is 24 questions and the score ranges from 0-4 with higher scores indicating a greater level of endorsement of controlled motivation. It will be measured at 2 time points. Autonomous motivation will be calculated by combining the identified, integrated, and intrinsic regulation subscales of the BREQ-3.
Measured: Baseline, 3 months
Change in mean daily step count by week over the study duration
Measured: Weekly up to 3 months (intervention period)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Aug 2026
- Study start12 Aug 2026
- Primary completionNov 2027 (estimated)
- Study completionNov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- More trials run by University of MichiganThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Michigan
- Sponsor type
- University, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Responsible party
- Principal investigator, Jessica Rachel Golbus, University of Michigan
- Investigators
- Jessica Golbus, MD, MS, Principal investigator, University of Michigan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07750262
- Sponsor's protocol ID
- HUM00290190
- Other IDs
- K23HL168220-01
- Acronym
- MOVIN-HF
- Status last verified
- Oct 2026
- First submitted
- 25 Jul 2026
- Last updated
- 23 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: After study completion, the investigators will generate a de-identified dataset that will be published online and which will be shared with other researchers upon request.